iBio, Inc. (NYSEAMERICAN:IBIO) Sees Significant Decrease in Short Interest

iBio, Inc. (NYSEAMERICAN:IBIO) was the target of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 202,800 shares, a decline of 12.2% from the November 15th total of 230,900 shares. Based on an average trading volume of 135,900 shares, the days-to-cover ratio is presently 1.5 days. Approximately 2.2% of the company’s shares are sold short.

iBio Stock Performance

Shares of NYSEAMERICAN:IBIO traded down $0.20 during mid-day trading on Friday, hitting $2.31. The stock had a trading volume of 132,576 shares, compared to its average volume of 1,093,175. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.91 and a current ratio of 0.91. iBio has a 12-month low of $1.02 and a 12-month high of $4.98.

iBio Company Profile

iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.